Terms: = Leukemia AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
36 results:
1. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
Roskoski R
Pharmacol Res; 2024 Jan; 199():107036. PubMed ID: 38096958
[TBL] [Abstract] [Full Text] [Related]
2. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.
Liang WW; Lu RJ; Jayasinghe RG; Foltz SM; Porta-Pardo E; Geffen Y; Wendl MC; Lazcano R; Kolodziejczak I; Song Y; Govindan A; Demicco EG; Li X; Li Y; Sethuraman S; Payne SH; Fenyö D; Rodriguez H; Wiznerowicz M; Shen H; Mani DR; Rodland KD; Lazar AJ; Robles AI; Ding L;
Cancer Cell; 2023 Sep; 41(9):1567-1585.e7. PubMed ID: 37582362
[TBL] [Abstract] [Full Text] [Related]
3. Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop.
Nejati R; Amador C; Czader M; Thacker E; Thakkar D; Dave SS; Dogan A; Duffield A; Goodlad JR; Ott G; Wasik MA; Xiao W; Cook JR
Am J Clin Pathol; 2023 Jun; 159(6):598-613. PubMed ID: 37085150
[TBL] [Abstract] [Full Text] [Related]
4. DNA damage to bone marrow stromal cells by antileukemia drugs induces chemoresistance in acute myeloid leukemia via paracrine FGF10-fgfr2 signaling.
Yu S; Ye J; Wang Y; Lu T; Liu Y; Liu N; Zhang J; Lu F; Ma D; Gale RP; Ji C
J Biol Chem; 2023 Jan; 299(1):102787. PubMed ID: 36509141
[TBL] [Abstract] [Full Text] [Related]
5. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.
Lazo De La Vega L; Comeau H; Sallan S; Al-Ibraheemi A; Gupta H; Li YY; Tsai HK; Kang W; Ward A; Church AJ; Kim A; Pinto NR; Macy ME; Maese LD; Sabnis AJ; Cherniack AD; Lindeman NI; Anderson ME; Cooney TM; Yeo KK; Reaman GH; DuBois SG; Collins NB; Johnson BE; Janeway KA; Forrest SJ
JCO Precis Oncol; 2022 Nov; 6():e2200390. PubMed ID: 36446043
[TBL] [Abstract] [Full Text] [Related]
6. Blockade of FGF2/fgfr2 partially overcomes bone marrow mesenchymal stromal cells mediated progression of T-cell acute lymphoblastic leukaemia.
Tian C; Li Y; Wang L; Si J; Zheng Y; Kang J; Wang Y; You MJ; Zheng G
Cell Death Dis; 2022 Nov; 13(11):922. PubMed ID: 36333298
[TBL] [Abstract] [Full Text] [Related]
7. Nuclear fgfr2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Cattaneo F; Ammendola R; Esposito G
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924850
[TBL] [Abstract] [Full Text] [Related]
8. Novel Mutations in a Lethal Case of Lymphomatous Adult T Cell Lymphoma with Cryptic Myocardial Involvement.
Hashemi Zonouz T; Abdulbaki R; Bandyopadhyay BC; Nava VE
Curr Oncol; 2021 Feb; 28(1):818-824. PubMed ID: 33562071
[TBL] [Abstract] [Full Text] [Related]
9. Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-fgfr2 rearrangement.
Carll T; Patel A; Derman B; Hyjek E; Lager A; Wanjari P; Segal J; Odenike O; Fidai S; Arber D
Blood Adv; 2020 Oct; 4(19):4924-4928. PubMed ID: 33049052
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA MEG3 Participates in Caerulein-Induced Inflammatory Injury in Human Pancreatic Cells via Regulating miR-195-5p/fgfr2 Axis and Inactivating NF-κB Pathway.
Chen X; Song D
Inflammation; 2021 Feb; 44(1):160-173. PubMed ID: 32856219
[TBL] [Abstract] [Full Text] [Related]
11. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Röllig C; Kramer M; Schliemann C; Mikesch JH; Steffen B; Krämer A; Noppeney R; Schäfer-Eckart K; Krause SW; Hänel M; Herbst R; Kunzmann V; Einsele H; Jost E; Brümmendorf TH; Scholl S; Hochhaus A; Neubauer A; Sohlbach K; Fransecky L; Kaufmann M; Niemann D; Schaich M; Frickhofen N; Kiani A; Heits F; Krümpelmann U; Kaiser U; Kullmer J; Wass M; Stölzel F; von Bonin M; Middeke JM; Thiede C; Schetelig J; Berdel WE; Ehninger G; Baldus CD; Müller-Tidow C; Platzbecker U; Serve H; Bornhäuser M
Blood; 2020 Aug; 136(7):823-830. PubMed ID: 32496541
[TBL] [Abstract] [Full Text] [Related]
12. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.
Zeidan AM; Wang R; Wang X; Shallis RM; Podoltsev NA; Bewersdorf JP; Huntington SF; Neparidze N; Giri S; Gore SD; Davidoff AJ; Ma X
Blood Adv; 2020 May; 4(10):2192-2201. PubMed ID: 32433746
[TBL] [Abstract] [Full Text] [Related]
13. Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M; Katoh M
Int J Mol Med; 2020 Feb; 45(2):279-297. PubMed ID: 31894255
[TBL] [Abstract] [Full Text] [Related]
14. Multipotent Mesenchymal Stromal Cells in Patients with Chronic Myeloid leukemia before Discontinuation of Tyrosine Kinase Inhibitors.
Petinati NA; Petrova AN; Chelysheva EY; Shukhov OA; Bykova AV; Nemchenko IS; Sats NV; Turkina AG; Drize NI
Bull Exp Biol Med; 2019 Aug; 167(4):580-583. PubMed ID: 31502137
[TBL] [Abstract] [Full Text] [Related]
15. Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia.
Jerchel IS; Hoogkamer AQ; Ariës IM; Boer JM; Besselink NJM; Koudijs MJ; Pieters R; den Boer ML
Sci Rep; 2019 Feb; 9(1):1875. PubMed ID: 30755670
[TBL] [Abstract] [Full Text] [Related]
16. Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment.
Shipounova IN; Petinati NA; Bigildeev AE; Sorokina TV; Kuzmina LA; Parovichnikova EN; Savchenko VG
Leuk Lymphoma; 2019 Aug; 60(8):2042-2049. PubMed ID: 30668205
[TBL] [Abstract] [Full Text] [Related]
17. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
[TBL] [Abstract] [Full Text] [Related]
18. RNA sequencing of esophageal adenocarcinomas identifies novel fusion transcripts, including NPC1-MELK, arising from a complex chromosomal rearrangement.
Wang Z; Cheng Y; Abraham JM; Yan R; Liu X; Chen W; Ibrahim S; Schroth GP; Ke X; He Y; Meltzer SJ
Cancer; 2017 Oct; 123(20):3916-3924. PubMed ID: 28640357
[TBL] [Abstract] [Full Text] [Related]
19. Genome-wide haplotype association study identify the fgfr2 gene as a risk gene for acute myeloid leukemia.
Lv H; Zhang M; Shang Z; Li J; Zhang S; Lian D; Zhang R
Oncotarget; 2017 Jan; 8(5):7891-7899. PubMed ID: 27903959
[TBL] [Abstract] [Full Text] [Related]
20. Estimation of the prevalence and direct medical costs of chronic myeloid leukemia in the I.R. of Iran in the era of tyrosine kinase inhibitors.
Daroudi R; Mirzania M; Nikravanfard N; Sadighi S; Sedighi Z; Zendehdel K
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e416-e422. PubMed ID: 26990676
[TBL] [Abstract] [Full Text] [Related]
[Next]
